Summary
4.25 -0.14(-3.19%)09/06/2024
Eagle Pharmaceuticals Inc (EGRX)
Eagle Pharmaceuticals Inc (EGRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.19 | -17.32 | -6.18 | 14.25 | -33.07 | -74.96 | -92.27 | -66.87 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.25 | |
| Open | 4.41 | |
| High | 4.41 | |
| Low | 4.13 | |
| Volume | 53,627 | |
| Change | -0.14 | |
| Change % | -3.19 | |
| Avg Volume (20 Days) | 81,184 | |
| Volume/Avg Volume (20 Days) Ratio | 0.66 | |
| 52 Week Range | 3.21 - 17.54 | |
| Price vs 52 Week High | -75.77% | |
| Price vs 52 Week Low | 32.40% | |
| Range | -3.63 | |
| Gap Up/Down | -0.24 | |
Fundamentals | ||
| Market Capitalization (Mln) | 55 | |
| EBIDTA | 62,327,000 | |
| PE Ratio | 5.3412 | |
| PEG Ratio | 0.9100 | |
| WallStreet Target Price | 17.00 | |
| Book Value | 19.2480 | |
| Earnings Per Share | 0.8500 | |
| EPS Estimate Current Quarter | 1.0500 | |
| EPS Estimate Next Quarter | 0.9300 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.8500 | |
| Revenues | ||
| Profit Marging | 0.0464 | |
| Operating Marging (TTM) | 0.1594 | |
| Return on asset (TTM) | 0.0663 | |
| Return on equity (TTM) | 0.0488 | |
| Revenue TTM | 257,551,008 | |
| Revenue per share TTM | 19.6840 | |
| Quarterly Revenue Growth (YOY) | -0.1280 | |
| Quarterly Earnings Growth (YOY) | -0.8710 | |
| Gross Profit (TTM) | 221,674,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 5.3412 | |
| Forward PE | 11.3379 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.2360 | |
| Revenue Enterprise Value | 0.4494 | |
| EBITDA Enterprise Value | 2.0711 | |
| Shares | ||
| Shares Outstanding | 12,958,200 | |
| Shares Float | 10,385,031 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.14 | |
| Insider (%) | 12.02 | |
| Institutions (%) | 81.81 | |
08/27 16:30 EST - globenewswire.com
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) serves as an additional and separate basis for delisting.
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) serves as an additional and separate basis for delisting.
04/15 07:00 EST - globenewswire.com
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
-- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo -- -- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo --
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
-- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo -- -- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo --
04/12 16:05 EST - globenewswire.com
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”), with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC.
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”), with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC.
02/09 12:15 EST - accesswire.com
Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66577&wire=1 or contact Joseph E. Levi, Esq.
Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66577&wire=1 or contact Joseph E. Levi, Esq.
02/09 12:00 EST - prnewswire.com
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX.
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX.
02/09 11:30 EST - accesswire.com
Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66572&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66572&wire=1 or contact Joseph E. Levi, Esq.
02/09 07:30 EST - accesswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals, Inc. Lawsuit - EGRX
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66547&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals, Inc. Lawsuit - EGRX
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66547&wire=1 or contact Joseph E. Levi, Esq.
02/09 05:45 EST - prnewswire.com
Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX
NEW YORK , Feb. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX
NEW YORK , Feb. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
02/09 05:00 EST - accesswire.com
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2023 and November 28, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before February 9, 2024.
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2023 and November 28, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before February 9, 2024.
02/08 18:30 EST - accesswire.com
Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66498&wire=1 or contact Joseph E. Levi, Esq.
Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66498&wire=1 or contact Joseph E. Levi, Esq.
02/08 16:30 EST - accesswire.com
Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) - February 9, 2024 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66490&wire=1 or contact Joseph E. Levi, Esq.
Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) - February 9, 2024 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66490&wire=1 or contact Joseph E. Levi, Esq.
02/08 16:15 EST - prnewswire.com
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES , Feb. 8, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX). Class Period: August 8, 2023 – November 28, 2023 Lead Plaintiff Deadline: February 9, 2024 If you wish to serve as lead plaintiff of the Eagle Pharmaceuticals lawsuit, you can submit your contact information at www.glancylaw.com/cases/Eagle-Pharmaceuticals-Inc-1/.
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES , Feb. 8, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX). Class Period: August 8, 2023 – November 28, 2023 Lead Plaintiff Deadline: February 9, 2024 If you wish to serve as lead plaintiff of the Eagle Pharmaceuticals lawsuit, you can submit your contact information at www.glancylaw.com/cases/Eagle-Pharmaceuticals-Inc-1/.
02/08 15:20 EST - accesswire.com
Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66485&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66485&wire=1 or contact Joseph E. Levi, Esq.
02/08 15:00 EST - businesswire.com
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Eagle Pharmaceuticals, Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ: EGRX) securities between August 8, 2023 and November 28, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On November 9, 2023, before the ma.
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Eagle Pharmaceuticals, Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ: EGRX) securities between August 8, 2023 and November 28, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On November 9, 2023, before the ma.
02/08 05:45 EST - prnewswire.com
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024
NEW YORK , Feb. 8, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 8, 2023 and November 28, 2023. If you suffered a loss on your investment in Eagle Pharmaceuticals, contact us about potential recovery by using the link below.
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024
NEW YORK , Feb. 8, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 8, 2023 and November 28, 2023. If you suffered a loss on your investment in Eagle Pharmaceuticals, contact us about potential recovery by using the link below.
02/08 04:00 EST - accesswire.com
FINAL DEADLINE FRIDAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2023 and November 28, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before February 9, 2024.
FINAL DEADLINE FRIDAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2023 and November 28, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before February 9, 2024.
02/07 15:20 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX
NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX
NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.